Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease
of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) characterized by destruction of the myelin sheath structure. The loss of myelin leads …

Multiple sclerosis is a leading cause of neurological disability in adults. Heterogeneity in
multiple sclerosis clinical presentation has posed a major challenge for identifying genetic …

Background The variation in multiple sclerosis (MS) disease severity is incompletely
explained by genetics, suggesting genetic and environmental interactions are involved …

Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes
CD19+ B‐cells, is approved to treat aquaporin 4 (AQP4) IgG‐seropositive neuromyelitis …

The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …

Background Multiple sclerosis is an autoimmune chronic inflammatory disease
characterized by selective destruction of myelin in the CNS neurons (including optic nerve) …

From the perspective of precision medicine, the challenge for the future is to improve the
accuracy of diagnosis, prognosis, and prediction of therapeutic responses through the …

Ocrelizumab is a humanized monoclonal antibody designed to bind to the CD20 molecule,
resulting in a rapid depletion of B-cells; however, it has been shown that lymphocyte …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central
nervous system. The immunopathology of MS involves both T and B lymphocytes. Rituximab …